SciClone (NASDAQ:SCLN), a U.S.-based pharmaceutical company that sells licensed drugs on the Chinese market, was down 21% for November after poor quarterly results. In this video, Motley Fool health care analyst David Williamson discusses how a price reduction imposed by the Chinese government on its lead drug, Zadaxin, affected sales. Though the company was able to mitigate the damage, the company's integration of its acquisition of NovaMed isn't going as hoped, which is another factor hurting the company at the moment. Given its strong cash flow, is the sell-off a buying opportunity, or is there additional uncertainty on the horizon?
Free Article
Join Over Half a 1 Million Premium Members And Get More In-Depth Stock Guidance and Research
Why SciClone Lost in November
By Dave Williamson and Max Macaluso
–
Dec 4, 2012 at 4:20PM
NASDAQ: SCLN
SciClone Pharmaceuticals, Inc.
This U.S.-based seller of licensed drugs in China had a tough quarter.
David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
Stocks Mentioned
SciClone Pharmaceuticals, Inc.
SCLN
Pfizer
PFE
$32.69
(-0.49%)
$0.16
Sanofi
SNY
$54.02
(-0.48%)
$0.26
Baxter International
BAX
$37.70
(-1.08%)
$0.41
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Here's Why SciClone Pharmaceuticals' Shares Are Soaring 14% Today
Why SciClone Pharmaceuticals Is Soaring Today
Why SciClone Pharmaceuticals, Inc. Is Surging Higher
SciClone Hires a CFO
SciClone Q4 Net Drops Steeply
462%
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Stock Advisor Returns
462%
S&P 500 Returns
125%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/23/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.